With only $1.5M cash and no financing lined up, INDP faces imminent going-concern risk. The strategic review likely targets a reverse merger or asset sale. Traders should watch for a dilutive offering, reverse split, or bankruptcy filing within weeks. The 51x share dilution from preferred conversion makes any recovery extremely challenging for common holders.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 15 $1.59entry
- T+1 · 6mo ago −4.40%α −4.34% · $1.52
- T+5 · 6mo ago −23.27%α −24.23% · $1.22
- T+20 · 5mo ago +132.08%α +129.96% · $3.69
- T+60 · 3mo ago −25.16%α −29.67% · $1.19
Price Chart
How similar events traded
Executive Summary
Indaptus Therapeutics reported Q1 2026 results with a net loss of $2.5M ($0.23/share), improved from $4.5M ($9.11/share) a year ago, driven by a 78% reduction in R&D spend as the company paused its Phase 1 study. Cash burn accelerated to $7.0M in operating cash flow, leaving only $1.5M in cash, roughly 2 months of runway, forcing a strategic review and potential sale or reverse merger. The preferred stock conversion eliminated overhang but diluted common shares massively (from 2.2M to 113.2M shares outstanding).
Key Financial Metrics
Key Facts
- Net loss improved to $2.5M from $4.5M YoY, but solely due to R&D cuts from $2.8M to $0.5M after halting the Phase 1 study
- Cash and equivalents fell 82% to $1.5M from $8.5M at year-end 2025, with operating cash burn of $7.0M in the quarter
- All Series AA and AAA preferred stock converted to common, increasing shares outstanding from 2.2M to 113.2M (51x dilution)
- Company explicitly states it needs additional capital and there is no assurance financing will be available
- Management is conducting a strategic review of development priorities and resource allocation, signaling potential pivot or sale
Financial Impact
Cash runway of ~2 months at current burn rate; $1.5M cash vs $7.0M quarterly operating cash use
Risk Factors
- Imminent going-concern risk, cash likely exhausted by mid-2026 without financing
- Massive dilution from preferred conversion (113M shares vs 2.2M) crushes per-share value
- No revenue, no pipeline advancement, and a strategic review that may result in a dilutive reverse merger or liquidation
- Nasdaq listing at risk if stock price remains below $1.00 (current market cap $4M)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295732 |
Track record
20 reports on INDP
4 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +59.35% at T+20 after the Jul 20, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 13, 20263d ago Press Release Neutral 4/10 Entry $3.17 Now $3.45 +8.83% settles Dec 15
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 3/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 22, 202625d ago SC 13D/A Neutral 4/10 Entry $3.16 Now $3.45 +9.18% settles Nov 20
- Oct 21, 202626d ago SC 13D/A Neutral 4/10 Entry $2.99 Now $3.45 +15.38% settles Nov 19
- Oct 20, 202627d ago 8-K Bearish 6/10 Entry $3.16 Now $3.45 −9.18% settles Nov 18
- Sep 30, 20266w ago 8-K Neutral 3/10 Entry $2.30 to $3.31 Now $3.45 +50.00% ▲ +43.70% +42.43% vs SPY
- Sep 9, 20269w ago 8-K Bearish 7/10 Entry $2.56 to $2.37 Now $3.45 −34.77% ▲ +7.42% +9.55% vs SPY
- Sep 4, 202610w ago 424B5 Bearish 6/10 Entry $1.85 to $2.59 Now $3.45 −86.49% ▼ −40.00% −38.29% vs SPY
- Sep 1, 202610w ago 8-K Bearish 5/10 Entry $1.13 to $2.32 Now $3.45 −205.31% ▼ −104.87% −103.69% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers